Additionally, the combination of anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) or anti-lymphocyte activation gene 3 (LAG3) with anti-PD1 antibodies has further increased tumor response rates through unleashing potent immune effector mechanisms [3,8]. The gene discussed is CTLA4; the disease is neoplasm.